Direct and crossover effects of brinzolamide, betaxolol, and latanoprost on choroidal thickness

References

• Rulo AH, Greve EL, Geijssen H, et al. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal pressure glaucoma. Ophthalmol 1996;103:1276–1282.
   Google Scholar
• DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44:119–129.
   PubMed Web of Science ®Google Scholar
• Berry DP, Van Buskirk EM, Shields MB. Betaxolol and timolol. A comparison of efficacy and side effects. Arch Ophthalmol 1984;102:42–45.
   PubMed Web of Science ®Google Scholar
• Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res 2010;29:144–168.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008;146:496–500.
   PubMed Web of Science ®Google Scholar
• Kara N, Demircan A, Karatas G, et al. Effects of two commonly used mydriatics on choroidal thickness: direct and crossover effects. J Ocul Pharmacol Ther 2014;30:366–370.
   PubMed Web of Science ®Google Scholar
• Martínez A, Sanchez-Salorio M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmol 2010;88:541–552.
   PubMed Web of Science ®Google Scholar
• Gürbüz O, Özsoy A, Yarangumeli A, et al. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand 2007;85:838–843.
   PubMedGoogle Scholar
• İnan UU, Ermiş SS, Yücel A, et al. The effects latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels a 3-month clinical trial. Acta Ophthalmol Scand 2003;81:155–160.
   PubMedGoogle Scholar
• Ishii K, Tomidokoro A, Nagara M, et al. Effects of topical latanoprost on optic nevre head circulation in rabbit, monkeys, and humans. Invest Ophthalmol Vis Sci 2001;42:2957–2963.
   PubMed Web of Science ®Google Scholar
• Erkin EF, Tarhan S, Kayıkcıoğlu OR, et al. Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma. Eur J Ophthalmol 2004;14:211–219.
   PubMed Web of Science ®Google Scholar
• Sponsel W, Mensah J, Kiel JW, et al. Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye. Am J Ophthalmol 2000;130:151–159.
   PubMed Web of Science ®Google Scholar
• Marcelo T, Nicolela AR, et al. A comparative study of the effects of Timolol and Latanoprost on blood flow velocity of the retrobulbar vessels. Am J Ophthalmol 1996;112:784–789.
   Google Scholar
• Januleviciene I, Haris A, Kageman L, et al. Comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand 2004;82:730–737.
   PubMedGoogle Scholar
• Sahinoglu-Keskek N, Canan H. Effect of latanoprost on choroidal thickness. J Glaucoma 2018;27:635–637.
   PubMed Web of Science ®Google Scholar
• Dong Y, Ishikawa H, Wu Y, et al. Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery. Jpn J Ophthalmol 2006;50:504–508.
   PubMed Web of Science ®Google Scholar
• Rassam SM, Patel V, Kohner EM. The effect of acetalozamide on the retinal circulation. Eye 1993;7:697–702.
   PubMed Web of Science ®Google Scholar
• Akyol N, Kalkışım A, Turk A, et al. Evaluation of the effects on choroid thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/timolol maleate 0.5% fixed combination. Cutan Ocul Toxicol 2017; 36:397–403.
   PubMed Web of Science ®Google Scholar
• Kadam RS, Jadhav G, Ogidigben M, et al. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metab Dispos 2011;39:1529–1537.
   PubMed Web of Science ®Google Scholar
• Vuori ML, Ali-Melkkila T, Kaila T, et al. Plasma and aqueous humour concentrations and systemic effects of topical betaxolol and timolol in man. Acta Ophthalmol (Copenh) 1993;71:201–206.
   PubMed Web of Science ®Google Scholar
• Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002; 47:6–12.
   PubMed Web of Science ®Google Scholar
• Schacknow PN, Samples JR. The glaucoma book, a practical, evidence-based approach to patient care. New York (NY): Springer; 2010.
   Google Scholar
• Drange S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131:699–708.
   PubMed Web of Science ®Google Scholar
• Orgul S, Kaiser HJ, Flammer J, et al. Systemic blood pressure and capillary blood-cell velocity in glaucoma patients: a preliminary study. Eur J Ophthalmol 1995;5:88–91.
   PubMedGoogle Scholar
• Charlson ME, de Moraes CG, Link A, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. Ophthalmology 2014;121:2004–2012.
   PubMed Web of Science ®Google Scholar
• Flammer J. The glaucomatous optic neuropathy: a reperfusion damage. Klin Monatsbl Augenheilkd 2001;218:290–291.
   PubMed Web of Science ®Google Scholar
• Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: players in the pathogenesis of glaucoma. Mol Vis 2008;14:224–233.
   PubMed Web of Science ®Google Scholar
• Mozaffarieh M, Flammer J. New insights in the pathogenesis and treatment of normal tension glaucoma. Curr Opin Pharmacol 2013;13:43–49.
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487–497.
   PubMed Web of Science ®Google Scholar